HOPA Highlights
At the Hematology/Oncology Pharmacy Association 2025 Annual Conference, Oncology Practice Management spoke with Iman Ahmed, PharmD, BCOP, Clinical Pharmacist Specialist, Ambulatory Hematology, at the University of Michigan, Rogel Cancer Center, Ann Arbor, MI, about how social determinants of health affect health inequities in hematologic malignancies and the provider’s role in mitigating these disparities, including research, advocacy, and the development of oncology-specific tools. Her data were presented at the conference.
Read More ›Research has shown that when patients receive care from providers who share similar racial or ethnic backgrounds, their health outcomes tend to improve. Read More ›
This new feature is a compendium of pioneering work by established and up-and-coming hematology oncology pharmacists and other healthcare providers working
in a variety of oncology settings who published abstracts in the Journal of Hematology Oncology Pharmacy, the official publication of the Hematology/Oncology Pharmacy Association (HOPA). Read More ›
The COVID-19 pandemic may have temporarily overshadowed the opioid crisis in the United States, but deaths related to opioid overdose have risen to an all-time high in the past year. Although largely driven by synthetic opioids such as illicit fentanyl, frequently prescribed opioids have played a role in opioid overdose and opioid use disorder as well. Read More ›
Thrombosis in patients with cancer may be a relatively common complication, but the treatment of venous thromboembolism (VTE) in this patient population is anything but simple. Patients with cancer have up to 6 times increased risk for recurrent VTE compared with patients without cancer, and they are also at higher risk for treatment-related side effects, such as bleeding. Furthermore, patients with cancer require longer-term use of anticoagulants, which raises concerns about quality of life and medication adherence. Read More ›
Lung cancer remains the leading cause of cancer death worldwide, but the treatment landscape is rapidly evolving. In the past 10 years alone, the number of drugs approved by the FDA for non–small-cell lung cancer (NSCLC) has exceeded the previous 10 decades combined. Read More ›